Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-473-7700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.07 million
Profitability
Miscellaneous
Employees18
OptionableOptionable
Geron (NASDAQ:GERN) Frequently Asked Questions
What is Geron's stock symbol?
Geron trades on the NASDAQ under the ticker symbol "GERN."
How were Geron's earnings last quarter?
Geron Co. (NASDAQ:GERN) announced its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.02. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.22 million. Geron had a negative net margin of 3,077.78% and a negative return on equity of 19.16%. View Geron's Earnings History.
When is Geron's next earnings date?
What price target have analysts set for GERN?
4 equities research analysts have issued twelve-month target prices for Geron's stock. Their predictions range from $1.50 to $7.00. On average, they anticipate Geron's share price to reach $3.5750 in the next year. This suggests a possible upside of 228.0% from the stock's current price. View Analyst Price Targets for Geron.
What is the consensus analysts' recommendation for Geron?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.
Has Geron been receiving favorable news coverage?
News coverage about GERN stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Geron earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Are investors shorting Geron?
Geron saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 35,699,111 shares, an increase of 2.2% from the December 14th total of 36,502,581 shares. Based on an average daily volume of 4,504,534 shares, the short-interest ratio is currently 7.9 days. Currently, 19.3% of the shares of the stock are short sold. View Geron's Current Options Chain.
Who are some of Geron's key competitors?
Some companies that are related to Geron include Inflarx (IFRX), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Y-mAbs Therapeutics (YMAB), Epizyme (EPZM), CytomX Therapeutics (CTMX), AC Immune (ACIU), Dynavax Technologies (DVAX), Revance Therapeutics (RVNC), ImmunoGen (IMGN), Radius Health (RDUS), Principia Biopharma (PRNB), G1 Therapeutics (GTHX), Intra-Cellular Therapies (ITCI) and Rocket Pharmaceuticals (RCKT).
Who are Geron's key executives?
Geron's management team includes the folowing people:
- Dr. John A. Scarlett, CEO, Pres & Director (Age 67)
- Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 49)
- Dr. Andrew J. Grethlein, Exec. VP of Devel. & Technical Operations (Age 54)
- Mr. Stephen N. Rosenfield, Exec. VP, Gen. Counsel & Corp. Sec. (Age 68)
- Ms. Melissa A. Kelly Behrs, Exec. VP of Bus. Devel., Portfolio & Alliance Management (Age 54)
Who are Geron's major shareholders?
Geron's stock is owned by many different of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.10%). Company insiders that own Geron stock include Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.
Which institutional investors are buying Geron stock?
How do I buy shares of Geron?
Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Geron's stock price today?
One share of GERN stock can currently be purchased for approximately $1.09.
How big of a company is Geron?
Geron has a market capitalization of $203.12 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.
What is Geron's official website?
How can I contact Geron?
Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]
MarketBeat Community Rating for Geron (NASDAQ GERN)
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
